Dr. Jonathan D. Jones, MD
Rheumatology (Rheumatology Physician)
- Medicare participating
At a glance
- Medical school
- University of Utah School of Medicine (2002)
- Years since graduation
- 24
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 191
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2002Medical school: University of Utah School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
OR license MD181303
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Good Samaritan Regional Medical Center Corvallis, OR
- Samaritan Albany General Hospital Albany, OR
- Samaritan PAcific Community Hospital Newport, OR
- Samaritan Lebanon Community Hospital Lebanon, OR
- Samaritan North Lincoln Hospital Lincoln City, OR
Medical groups
- Good Samaritan Hospital Corvallis (380 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 191
- Services billed
- 658
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 327 | 155 |
| Established patient office or other outpatient visit, 40-54 minutes | 35 | 30 |
| Established patient office or other outpatient visit, 20-29 minutes | 26 | 25 |
| New patient office or other outpatient visit, 45-59 minutes | 17 | 17 |
| Aspiration and/or injection of fluid from large joint | 16 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Corvallis, OR | 358 |
| Prednisone Other prescribers in Corvallis, OR | 336 |
| Hydroxychloroquine Sulfate Other prescribers in Corvallis, OR | 273 |
| Leflunomide Other prescribers in Corvallis, OR | 106 |
| Sulfasalazine Dr (sulfasalazine) Other prescribers in Corvallis, OR | 94 |
| Rinvoq (upadacitinib) | 66 |
| Gabapentin Other prescribers in Corvallis, OR | 66 |
| Meloxicam Other prescribers in Corvallis, OR | 63 |
| Allopurinol Other prescribers in Corvallis, OR | 61 |
| Enbrel Sureclick (etanercept) Other prescribers in Corvallis, OR | 59 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 11 payments worth $376 in total to this clinician.
| Argenx US, Inc. | $245 |
|---|---|
| Novo Nordisk Inc | $75.19 |
| UCB, Inc. | $38.44 |
| AstraZeneca Pharmaceuticals LP | $17.41 |
| Food and Beverage | $376 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $83,306 in research payments for these studies, mostly to the institutions running them.
- Quincy Model A Phase 3 Randomized Double Blinded Placebo Controlled Multicenter Trial to Evaluate the Efficacy Safety and Tolerability of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Patie…
Argenx US, Inc. - A Study of Baricitinib in Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT04086745 - A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocortico…
Novartis Pharmaceuticals Corporation - A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease-modifying Anti-rheumatic Drugs
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.